The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2023 | Advances in the treatment of pancreatic cancer
Thomas Seufferlein, MD, PhD, Ulm University, Ulm, Germany, provides an overview of developments in treating pancreatic cancer. There are many novel targets (e.g., Claudin 18.2) and studies of interest in the field of pancreatic cancer, such as vaccination in the adjuvant setting. The number of inhibitors for KRAS mutations in pancreatic cancer is on the rise, and CD40-targeting agents are now also available. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
